Evidence map›Paper›PMID 41084726›Full record

ArticleCureus2025

The Survival Rate of Hospitalized Lupus Patients With Overlap Disease.

Jaafar Al-Sadiq Jaf, Seyedeh Tahera Faezi, Amir Kasaeian

Erratum issuedAbstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Jaafar Al-Sadiq JafStroke, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, GBR.
Seyedeh Tahera FaeziRheumatology, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, IRN.
Amir KasaeianStatistics, Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, IRN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease associated with a rate of mortality during hospitalization. On the other hand, SLE can be associated with other autoimmune diseases with different morbidity and mortality, so a combination of SLE and other autoimmune diseases, as overlap diseases, may increase the risk of morbidity and mortality. The aim of this study was to determine the survival rate of hospitalized SLE patients who also had other autoimmune diseases. Method We used a retrospective data collection from the inpatient files collected over the past 10 years in the Shariati Hospital, Rheumatology Department, Tehran University of Medical Sciences. Results We identified 219 patients with SLE who overlapped with other autoimmune diseases. Nearly 90% (n=197) were female patients. The mean age of patients was 37.9 years. The most common overlap autoimmune disease alongside SLE was anti-phospholipid syndrome (APS; n=99; 45.4%), followed by rheumatoid arthritis (RA) and scleroderma (n=29; 13.3% each). We had eight (3.7%) deaths in the hospitalized patients, of which six (75.0%) were female patients. The SLE patients who had overlap with APS, scleroderma, and RA died during hospitalization. The general survival rate of SLE patients with at least one autoimmune disease was around 75% (n=164), and the female patients had a better survival rate than the male patients (n=152; 77.0% and n=12; 75.0%, respectively). Infection was the main cause of mortality. Conclusion The general survival rate of SLE patients with at least one autoimmune disease was around 75%. Presence of overlap with APS, scleroderma and RA, and male gender worsened the survival rate.

Indexed as

autoimmune diseasemortalityoverlap diseasessurvival ratesystemic lupus erythematosus

Identifiers

PMID41084726
PMCPMC12515529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.